Condition
Acute Idiopathic Thrombocytopenic Purpura
Total Trials
2
Recruiting
0
Active
0
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by E5501 40 Mg 2 X 20mg Tablets Orally Fasted
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 2 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
1Total
Phase 1 (1)
Trial Status
Completed1
Unknown1
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 1 completed trials
Clinical Trials (2)
Showing 2 of 2 trials
NCT01327872Phase 1Completed
Subject Variability in Two Lots of E5501 Administered to Fed and Fasted Healthy Subjects
NCT00331357UnknownPrimary
Cohort of Children With Acute Immune or Idiopathic Thrombocytopenic Purpura (ITP) : a Prospective Study in Pays De La Loire
Showing all 2 trials
Research Network
Common Treatments
- E5501 40 Mg 2 X 20mg Tablets Orally Fasted1
- E5501 40 Mg 2 X 20mg Tablets Orally With Food1
- E5501 40mg 2 X 20mg Tablets Orally Fasted1
Active Sponsors
- University Hospital, Angers1
- Ministry of Health, France1
- Eisai Inc.1
Top Investigators
Eisai Inc.
UH of Angers
Related Conditions
- Chronic Thrombocytopenia1
- Purpura Thrombocytopenic Idiopathic1